Cargando…

Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study

BACKGROUND: The COVID-19 pandemic disrupted Alzheimer disease randomized clinical trials (RCTs), forcing investigators to make changes in the conduct of such trials while endeavoring to maintain their validity. Changing ongoing RCTs carries risks for biases and threats to validity. To understand the...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, Lon S., Qiu, Yuqi, Thomas, Ronald G., Evans, Carol, Jacobs, Diane M., Jin, Shelia, Kaye, Jeffrey A., LaCroix, Andrea Z., Messer, Karen, Salmon, David P., Sano, Mary, Schafer, Kimberly, Feldman, Howard H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686345/
https://www.ncbi.nlm.nih.gov/pubmed/34930444
http://dx.doi.org/10.1186/s13195-021-00938-w
_version_ 1784617999529934848
author Schneider, Lon S.
Qiu, Yuqi
Thomas, Ronald G.
Evans, Carol
Jacobs, Diane M.
Jin, Shelia
Kaye, Jeffrey A.
LaCroix, Andrea Z.
Messer, Karen
Salmon, David P.
Sano, Mary
Schafer, Kimberly
Feldman, Howard H.
author_facet Schneider, Lon S.
Qiu, Yuqi
Thomas, Ronald G.
Evans, Carol
Jacobs, Diane M.
Jin, Shelia
Kaye, Jeffrey A.
LaCroix, Andrea Z.
Messer, Karen
Salmon, David P.
Sano, Mary
Schafer, Kimberly
Feldman, Howard H.
author_sort Schneider, Lon S.
collection PubMed
description BACKGROUND: The COVID-19 pandemic disrupted Alzheimer disease randomized clinical trials (RCTs), forcing investigators to make changes in the conduct of such trials while endeavoring to maintain their validity. Changing ongoing RCTs carries risks for biases and threats to validity. To understand the impact of exigent modifications due to COVID-19, we examined several scenarios in symptomatic and disease modification trials that could be made. METHODS: We identified both symptomatic and disease modification Alzheimer disease RCTs as exemplars of those that would be affected by the pandemic and considered the types of changes that sponsors could make to each. We modeled three scenarios for each of the types of trials using existing datasets, adjusting enrollment, follow-ups, and dropouts to examine the potential effects COVID-19-related changes. Simulations were performed that accounted for completion and dropout patterns using linear mixed effects models, modeling time as continuous and categorical. The statistical power of the scenarios was determined. RESULTS: Truncating both symptomatic and disease modification trials led to underpowered trials. By contrast, adapting the trials by extending the treatment period, temporarily stopping treatment, delaying outcomes assessments, and performing remote assessment allowed for increased statistical power nearly to the level originally planned. DISCUSSION: These analyses support the idea that disrupted trials under common scenarios are better continued and extended even in the face of dropouts, treatment disruptions, missing outcomes, and other exigencies and that adaptations can be made that maintain the trials’ validity. We suggest some adaptive methods to do this noting that some changes become under-powered to detect the original effect sizes and expected outcomes. These analyses provide insight to better plan trials that are resilient to unexpected changes to the medical, social, and political milieu.
format Online
Article
Text
id pubmed-8686345
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86863452021-12-20 Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study Schneider, Lon S. Qiu, Yuqi Thomas, Ronald G. Evans, Carol Jacobs, Diane M. Jin, Shelia Kaye, Jeffrey A. LaCroix, Andrea Z. Messer, Karen Salmon, David P. Sano, Mary Schafer, Kimberly Feldman, Howard H. Alzheimers Res Ther Research BACKGROUND: The COVID-19 pandemic disrupted Alzheimer disease randomized clinical trials (RCTs), forcing investigators to make changes in the conduct of such trials while endeavoring to maintain their validity. Changing ongoing RCTs carries risks for biases and threats to validity. To understand the impact of exigent modifications due to COVID-19, we examined several scenarios in symptomatic and disease modification trials that could be made. METHODS: We identified both symptomatic and disease modification Alzheimer disease RCTs as exemplars of those that would be affected by the pandemic and considered the types of changes that sponsors could make to each. We modeled three scenarios for each of the types of trials using existing datasets, adjusting enrollment, follow-ups, and dropouts to examine the potential effects COVID-19-related changes. Simulations were performed that accounted for completion and dropout patterns using linear mixed effects models, modeling time as continuous and categorical. The statistical power of the scenarios was determined. RESULTS: Truncating both symptomatic and disease modification trials led to underpowered trials. By contrast, adapting the trials by extending the treatment period, temporarily stopping treatment, delaying outcomes assessments, and performing remote assessment allowed for increased statistical power nearly to the level originally planned. DISCUSSION: These analyses support the idea that disrupted trials under common scenarios are better continued and extended even in the face of dropouts, treatment disruptions, missing outcomes, and other exigencies and that adaptations can be made that maintain the trials’ validity. We suggest some adaptive methods to do this noting that some changes become under-powered to detect the original effect sizes and expected outcomes. These analyses provide insight to better plan trials that are resilient to unexpected changes to the medical, social, and political milieu. BioMed Central 2021-12-20 /pmc/articles/PMC8686345/ /pubmed/34930444 http://dx.doi.org/10.1186/s13195-021-00938-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Schneider, Lon S.
Qiu, Yuqi
Thomas, Ronald G.
Evans, Carol
Jacobs, Diane M.
Jin, Shelia
Kaye, Jeffrey A.
LaCroix, Andrea Z.
Messer, Karen
Salmon, David P.
Sano, Mary
Schafer, Kimberly
Feldman, Howard H.
Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study
title Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study
title_full Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study
title_fullStr Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study
title_full_unstemmed Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study
title_short Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study
title_sort impact of potential modifications to alzheimer’s disease clinical trials in response to disruption by covid-19: a simulation study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686345/
https://www.ncbi.nlm.nih.gov/pubmed/34930444
http://dx.doi.org/10.1186/s13195-021-00938-w
work_keys_str_mv AT schneiderlons impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy
AT qiuyuqi impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy
AT thomasronaldg impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy
AT evanscarol impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy
AT jacobsdianem impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy
AT jinshelia impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy
AT kayejeffreya impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy
AT lacroixandreaz impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy
AT messerkaren impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy
AT salmondavidp impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy
AT sanomary impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy
AT schaferkimberly impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy
AT feldmanhowardh impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy